Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...
The non-cystic fibrosis bronchiectasis market is driven by rising prevalence linked to respiratory infections, autoimmune diseases, and COPD. Increasing awareness among healthcare providers and ...
(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).
In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...
A recent study showed that the COPD assessment test was reliable and responsive for assessing health status in fibrotic ...
What is cystic fibrosis liver disease? Liver disease associated with cystic fibrosis (CF) has been increasingly diagnosed during recent years, most likely due to the combined effect of systematic ...
Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA ...
In sarcoidosis, fibrosis in affected organs ... align with reports of elevated matrix metalloproteinases and other markers of tissue disruption in pulmonary, cardiac and cutaneous sarcoidosis.9 10 As ...
Current studies indicate that IL-17B is associated with the occurrence and progression of pulmonary fibrosis and systemic sclerosis. Notably, in systemic sclerosis, there is no statistically ...
Most cases gain good recovery after surgery, while some patients may experience knee stiffness, which is characterized by joint fibrosis, leading to reduced joint mobility, pain, and dysfunction.